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accepted Octoberre-clinical diastolic dysfunction (PDD) has been broadly deﬁned as left ventricular diastolic dysfunction without the
diagnosis of congestive heart failure (HF) and with normal systolic function. PDD is an entity that remains poorly
understood, yet has deﬁnite clinical signiﬁcance. Although few original studies have focused on PDD, it has been
shown that PDD is prevalent, and that there is a clear progression from PDD to symptomatic HF including dyspnea,
edema, and fatigue. In diabetic patients and in patients with coronary artery disease or hypertension, it has been
shown that patients with PDD have a signiﬁcantly higher risk of progression to heart failure and death compared
with patients without PDD. Because of these ﬁndings and the increasing prevalence of the heart failure epidemic,
it is clear that an understanding of PDD is essential to decreasing patients’ morbidity and mortality. This review will
focus on what is known concerning pre-clinical diastolic dysfunction, including deﬁnitions, staging, epidemiology,
pathophysiology, and the natural history of the disease. In addition, given the paucity of trials focused on PDD
treatment, studies targeting risk factors associated with the development of PDD and therapeutic trials for heart
failure with preserved ejection fraction will be reviewed. (J Am Coll Cardiol 2014;63:407–16) ª 2014 by the
American College of Cardiology FoundationHeart failure (HF) is an epidemic that, on the basis of 2013
estimates, affects 5.1 million American adults, and this
epidemic will grow 25% by 2030 as the U.S. population
continues to age (1). HF is a clinical diagnosis (2). An
ejection fraction (EF) of <50% in a patient with HF
symptoms is termed heart failure with reduced ejection
fraction (HFrEF), and an EF of 50% in a patient with
heart failure symptoms is termed heart failure with pre-
served ejection fraction (HFpEF). Studies have de-
monstrated that HFpEF is as prevalent as HFrEF (3). It is
important to note that these terms are not mutually exclu-
sive, as nearly all patients with systolic dysfunction have
some degree of concomitant diastolic dysfunction (4). Yet,
the converse does not hold, which suggests that there is an
unclear relationship between systolic dysfunction (SD) and
diastolic dysfunction (DD).
Although the endpoint of HF and clinical symptoms may
be similar in both categories, the pathophysiology of SD
and DD are quite different. For example, studies have
indicated that, although SD seems largely a disease of
calcium handling, DD seems to be a disease of increasedrtment of Internal Medicine, Mayo Clinic and Foundation,
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15, 2013.myoﬁlament sensitivity to calcium (5,6). This highlights the
importance of continued research at the molecular and
clinical level for DD to allow for greater understanding and
development of effective treatment options.
The American College of Cardiology and American
Heart Association have categorized HF into 4 stages: stage
A is deﬁned as high risk for HF without structural heart
disease or symptoms of HF; stage B is deﬁned as structural
heart disease without signs or symptoms of HF; stage C is
deﬁned as symptomatic HF; and stage D is HF refractory to
treatment (7).
Pre-clinical diastolic dysfunction (PDD), deﬁned as
diastolic dysfunction with normal systolic function and no
symptoms of HF, therefore, resides in stage B according to
the American College of Cardiology/American Heart
Association scheme (7). The importance of PDD is evident
in that even after controlling for comorbidities, PDD has
been shown to be associated with development of HF and is
predictive of all-cause mortality (4,8). Also, advanced
diastolic dysfunction is associated with reduced quality of life
and structural abnormalities that reﬂect increased cardio-
vascular risk (9).
Despite the seemingly simplistic deﬁnition of PDD, truly
understanding diastolic dysfunction, HF symptoms, and
their relationship is exceedingly complex. This complexity
stems from the fact that in addition to diastolic dysfunction,
comorbid conditions, including pulmonary, renal, and
hematologic dysfunction, play an important role in devel-
opment of symptomatic HF (Fig. 1). It has been recognized
that although some patients with normal EF may have
overt HF symptoms or HFpEF, others may have marked
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Wan et al. JACC Vol. 63, No. 5, 2014
Pre-Clinical Diastolic Dysfunction February 11, 2014:407–16
408impairment in diastolic function
that may be associated with no
symptoms or PDD (10).
Additionally, it has been shown
that left ventricular (LV) function
measured at rest can differ signif-
icantly from exercise tolerance and
severity of HF symptoms (11).
Therefore, exercise intolerance has
signiﬁcant diagnostic implications.
Cardiopulmonary exercise testing,
including determination of peak
oxygen uptake, is an objective
method used to determine the
functional capacity of a patient
with HF and for determination of
disease severity (12). Recent pub-
lished data has suggested the
importance of measuring diastolic
and peripheral function variables
during exercise, which may not
correlate to rest measurements, to
better characterize HF severityFigure 1
Cardiovascular and Noncardiac Risk Factors in the
Development and Progression of PDD and HFpEF
Cardiovascular risk factors contribute to the development of pre-clinical diastolic
dysfunction (PDD) (stage B). Both cardiovascular and noncardiac risk factors
contribute to the progression from PDD to symptomatic heart failure with
preserved ejection fraction (HFpEF) (stage C/D). Although survival decreases
dramatically in symptomatic heart failure, the duration of stages A and B heart
failure with regards to survival remains to be fully elucidated.(13–15). Future studies in PDD should include exercise
testing, which would allow for greater diagnostic accuracy as
well as advance the understanding of PDD.
Assessment of DD
Although systolic function is well characterized by deter-
minations of ejection fraction, diastolic function character-
ization of the heart’s stiffness, relaxation, and pressure
changes is more difﬁcult. Invasive measures of rate of LV
pressure decline, LV relaxation time constant, and stiffness
modulus can characterize diastolic function. Echocardiog-
raphy as a common noninvasive imaging technique is useful
in determining the presence of SD or DD. In diastole, the
LV ﬁlling pattern consists of 2 phases: early (E) and late or
atrial contraction (A). The E/A ratio is used as an estimate
of the relaxation pattern of the ventricle. Furthermore, tissue
Doppler imaging can be used to measure myocardial motion,
speciﬁcally the amount the mitral annulus recoils toward the
base during early diastole (e0). The LV ﬁlling pressures can
be estimated by the E/e0 ratio.
DD is categorized by Doppler echocardiographic ﬁndings
into the following progression: 1) mild (Grade I or Ia),
deﬁned as impaired relaxation without or with mild evidence
of increased ﬁlling pressures, respectively; 2) moderate
(Grade II), deﬁned as impaired relaxation associated with
moderate elevation of ﬁlling pressures or pseudonormal
ﬁlling; and 3) severe, deﬁned as advanced reduction in
compliance or reversible (Grade III) or ﬁxed (Grade IV)
restrictive ﬁlling (16,17).
To better understand and characterize the pathophysi-
ology of diastolic dysfunction, recent imaging research has
focused on using echocardiographic strain rate imaging.As the apex of the heart stays relatively stationary during the
cardiac contraction and relaxation cycle, the base moves
toward the apex during systole and retracts during diastole.
Therefore, the velocity at the apex is zero while the velocity
at the base during cardiac contraction and relaxation is at
maximum. By characterizing the rate of change of velocity
throughout the heart, or the amount of deformity of cardiac
muscle, strain rate can be calculated (18). Although strain
rate imaging has not been ofﬁcially incorporated into the
diastolic classiﬁcation algorithm, it has shown promise in
differentiating between those with and without diastolic
dysfunction (19). However, recent evidence demonstrates
that peak strain is not only dependent on ventricular relax-
ation, but also on restoring forces and early diastolic load as
well (20). Given the recent new evidence on limitations of
using strain rate for characterizing ventricular relaxation, it
remains to be seen how clinically useful strain rate imaging
will be compared with traditional methods for diastolic
dysfunction determination.
Cardiac magnetic resonance (CMR) imaging has long
been used for assessment of systolic function, but recent
efforts have been made to apply CMR techniques to eval-
uation of diastolic function. Tagged magnetic resonance
imaging of the heart has the potential as a noninvasive
technique to provide myocardial strain and deformation
information. CMR offers tremendous spatial resolution
advantages when compared with echocardiography, and can
accurately assess left atrial size and transmitral ﬂow (21).
However, the limited temporal resolution of magnetic
resonance imaging along with the high costs associated with
its use compared with conventional echocardiography limits
CMR’s widespread use.
Table 1 Prevalence of PDD
PDD (Redﬁeld et al. [4])
General adult population
All 27.4
Men 28.5
Women 26.4
High-risk population*
All 64.1
Men 63.3
Women 64.7
Elderly Population in Central Italy (25)
Men
All 35.8
Age 65 to 74 yrs 31.3
Age >74 yrs 44.2
Women
All 35.0
Age 65 to 74 yrs 30.0
Age >74 yrs 44.0
Framingham Heart Study (24)
General adult population 36.0
Australian population (9)
General adult population,
PDD with moderate to severe DD
4.9
Values are % with PDD. *The high-risk population was deﬁned by age 65 years and hypertension
or coronary artery disease.
DD ¼ diastolic dysfunction; PDD ¼ pre-clinical diastolic dysfunction.
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Given the nuances in deﬁning ventricular DD and HF, and
the lack of PDD as a common diagnostic code, exact
measurements of PDD prevalence are difﬁcult. Previously,
Fischer et al. (22) found an overall prevalence of diastolic
abnormalities to be 11.1% in a randomly selected sample
from the MONICA (Monitoring Trends and Determinants
on Cardiovascular Diseases) project, and Kuznetsova et al.
(23) found an overall prevalence of 27.3% for DD. Despite
the valuable DD prevalence data provided by these studies,
a limitation is that this data is for DD as a whole without
regard to symptoms, that is, it does not distinguish between
patients with PDD and those with HFpEF.
Currently, there are 4 original publications that have
contributed most to our understanding of PDD epidemi-
ology (4,9,24,25).
Redﬁeld et al. (4) conducted a survey of 2,042 randomly-
selected residents of Olmsted County, Minnesota, age 45
years and older, from June 1997 through September 2000.
Participants underwent Doppler echocardiographic assess-
ment of systolic and diastolic function, and the presence of
HF diagnosis was determined by review of themedical record.
Abhayaratna et al. (9) conducted a cross-sectional survey
of 1,275 randomly-selected residents of Canberra, Australia,
age 60 to 86 years, between February 2002 and June 2003.
Participants underwent Doppler echocardiography and
completed a self-administered questionnaire regarding their
medical history that was cross-referenced with documenta-
tion in the medical records. Abhayaratna et al. (9) found on
echocardiography that 23.5% and 5.6% of the population
had mild and moderate-to-severe DD, respectively.
In both studies, subjects with DD but without an HF
diagnosis by history or clinical records were considered to
have PDD (4,9). Redﬁeld et al. (4) found a prevalence of
20.6% for mild PDD and a prevalence of 6.8% for moderate
to severe PDD in the general adult population. High-risk
groups, or patients age 65 years with diagnoses of hyper-
tension or coronary artery disease, were found to have
a higher prevalence of PDD: 47.6% for mild PDD and
16.5% for moderate to severe PDD (Table 1) (4).
Redﬁeld et al. (4) found that, even among those subjects
with moderate or severe diastolic dysfunction, less than one-
half had recognized HF and the majority were, therefore, in
the pre-clinical stage of disease. This result was consistent
with the ﬁndings of Abhayaratna et al. (9), who found that
86% of subjects with moderate to severe DD with normal EF
were in the pre-clinical stage of disease as assessed by Fra-
mingham criteria. Abhayaratna et al. (9) also found that 36%
of these same patients were asymptomatic as judged by New
York Heart Association functional classiﬁcation (4,9,26).
Similarly, Lam et al. (24) found in the Framingham
cohort of 1,038 elderly patients that the prevalence of PDD
was 36% using Doppler echocardiographic data and evalu-
ating for HF symptoms of dyspnea, edema, and exertional
fatigue.Both Redﬁeld et al. (4) and Abhayaratna et al. (9) found
that the prevalence of diastolic dysfunction increased with
age; the presence of cardiovascular comorbidities such as
hypertension, obesity, coronary artery disease, history of
myocardial infarction, and cardiomyopathies; diabetes; and
systolic dysfunction. Abhayaratna et al. (9) also found that
clinical predictors of DD with normal EF included hyper-
tension, angina, myocardial infarction, and obesity. They
also reported that the rates of isolated DD, that is DD with
normal EF, increased with age (4,9). In the PREDICTOR
(Assessing the prevalence of asymptomatic cardiac dysfunc-
tion and heart failure) investigation, an Italian population of
1,720 elderly subjects age 65 to 84 years, Mureddu et al. (25)
found that 35.4% of the population had PDD (25). Doppler
echocardiographic data was used to evaluate cardiac func-
tion, and HF was deﬁned on the basis of history and
physical examination using the European Society of Cardi-
ology guidelines, with each subject evaluated by a panel of
3 cardiologists.
Another ﬁnding of Abhayaratna et al. (9) was that
moderate to severe DD with normal EF was independently
associated with structural abnormalities (increased LV mass
and left atrial volume) that reﬂect increased cardiovascular
risk, with increased circulating amino-terminal pro–B-type
natriuretic peptide concentrations, and with decreased
quality of life (9). Similarly, Redﬁeld et al. (4) determined
that increasing severity of PDD was associated with higher
mean LV mass index and mean left atrial volume index.
Furthermore, multivariate analysis revealed that DD was
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age, sex, and EF (4).
Two additional comorbidities that have profound impact
on DD are chronic obstructive pulmonary disease (COPD)
and anemia. COPD and HF are often comorbid conditions
that make accurate diagnosis challenging, as the presenting
symptoms for both of these entities can be similar. However,
lung pathology decreases cardiopulmonary reserve and may
convey an overall poorer prognosis (27,28). Anemia is also an
important comorbid condition in cardiac dysfunction, stem-
ming from hemodilution, decreased red blood cell produc-
tion, and concurrent renal disease. Anemia has been shown
to convey a worse prognosis to those with heart failure (29).
Aging is one of the most profound factors that inﬂuences
PDD and the development of HFpEF. Although the work
of both Redﬁeld et al. (4) and Abhayaratna et al. (9) show
that DD increases with age, this remains a topic requiring
further exploration given the lack of age-adjusted reference
standards for DD measurements. A better understanding of
normal aging with regard to diastolic function would allow
for greater understanding of PDD and subsequent devel-
opment of HFpEF.
In summary, the prevalence of PDD in the general adult
population is approximately 20% to 30%, with increasing age,
coronary artery disease, cardiovascular comorbidities, and
diabetes as independent risk factors for development of PDD.
Pathophysiology
Diastole encompasses the isovolumetric relaxation and ﬁlling
phases of the cardiac cycle and includes active and passive
components. Diastolic ﬁlling of the left ventricle (LV) is
generally biphasic, with rapid ﬁlling in early diastole, and
late ﬁlling is determined by atrial contraction, left atrial
pressure, and LV operating chamber stiffness (30). DD
refers to abnormal mechanical properties of the myocardium
and includes abnormal LV diastolic distensibility, impaired
ﬁlling, and slow or delayed relaxation (30). In DD, the
ventricle cannot accept blood at low pressures and ventric-
ular ﬁlling is slow or incomplete unless atrial pressure rises
(31). Therefore, there is an increased dependence on ﬁlling
through atrial contraction and there are higher atrial
pressures to maintain ﬁlling or cardiac output (32–34). With
regards to relaxation, any mechanism that interferes with
actin-myosin cross-bridge detachment or with removing
calcium from the cytosol can delay this process (35).
DD during the late ﬁlling phase of diastole can be a result
of increased LV operating stiffness (diastolic stiffness), which
is determined mainly by myocardial mass and myocardial
composition. In fact, numerous factors can inﬂuence LV
stiffness including age, increased LV wall thickness relative
to cavity size (such as in hypertension or aortic stenosis),
intracellular changes in titin or microtubules, extracellular
changes in collagen, and inﬁltration (e.g., amyloidosis) (35–39).
In addition, neurohormonal and cardiac endothelial activity
also modulate ventricular stiffness and relaxation (31).Although LV DD is known to be associated with the
development of left ventricular hypertrophy (LVH), inves-
tigations in both human and animal models of hypertension
suggest that early LV DD may precede the development of
LVH. Dupont et al. (40) evaluated LV DD in spontane-
ously hypertensive rats at different ages and tested whether
LV DD is associated with abnormal intracellular calcium
homeostasis. The authors reported that LV myocardial DD
precedes LVH in 3-week-old spontaneously hypertensive
rats and was associated with high diastolic intracellular
calcium concentration, possibly due to decreased SERCA
2a (sarcoplasmic reticulum calcium ATPase isoform 2a) and
p16-PLB (phospholamban Ser16) protein levels. Previ-
ously, LVH regression was identiﬁed as a relevant marker of
signiﬁcant improvement in LV diastolic function. Never-
theless, to this extent, the published report lacks consistent
data. For instance, a previous double-blind, randomized
trial reported signiﬁcant LVH regression with antihy-
pertensive treatment (enalapril or nifedipine), but also re-
ported little change in traditional Doppler diastolic
parameters (41). In contrast, an experimental LVH model
that demonstrated beneﬁcial effects of phosphodiesterase-5
inhibition on LVH failed to properly predict the results of
the phosphodiesterase-5 inhibition to improve clinical
status and exercise capacity in diastolic HF (RELAX study
[PhosphodiesteRasE-5 Inhibition to Improve CLinical
Status and EXercise Capacity in Diastolic Heart Failure])
(42,43). Future therapeutic studies are needed to determine
whether the regression of LVH or the improvement of
diastolic function would prevent the progression from PDD
to HFpEF.
Additionally, recent evidence suggests that contractile
dysfunction and myocardial remodeling may play a signiﬁ-
cant role in the pathophysiology of HFpEF. Although
contractile dysfunction is traditionally associated with
HFrEF, Dunlay et al. (44) showed that patients with
HFpEF demonstrated a progressive decline in ejection
fraction over time. However, this hypothesis will require
further conﬁrmatory investigations.
Interesting recent work in animal and human models have
implicated titin isoform shift, oxidative stress, nitric oxide
synthase dysfunction, and myosin-binding protein C in dia-
stolic dysfunction. Titin isoform shift, or the overexpression
of the stiff isoform of titin, has been found in endomyocardial
biopsy samples of patients withHFpEF (45). In patients with
type 1 diabetes, advanced glycation end products and oxida-
tive stress have been found to be associated with LV
dysfunction (46). Nitric oxide is a known mediator of cardiac
relaxation, and cardiac oxidation leading to uncoupling of
cardiac nitric oxide synthase results inDD (47). Last, myosin-
binding protein C, a protein located in crossbridge zones of
muscle sarcomeres, is important in regulating muscle
contraction. Phosphorylation of this important protein leads
to deregulations of cardiac muscle contraction and subsequent
dysfunction of the ventricles (48). Indeed, Paulus and
Tschope (49) describe a paradigm shift in thinking ofHFpEF
JACC Vol. 63, No. 5, 2014 Wan et al.
February 11, 2014:407–16 Pre-Clinical Diastolic Dysfunction
411as a process of comorbid conditions leading to a systemic
inﬂammatory state and microvascular inﬂammation, rather
than focusing on myocardial structure and function.
Natural History of PDD
Currently, there are only a few original publications that have
speciﬁcally addressed the natural history of PDD (50).
Additionally, the natural history of PDD is largely deter-
mined by the underlying comorbidities, which provide unique
prognostic determinations to those with DD. Mohammed
et al. (51) demonstrated that comorbidities among those with
HFpEF led to different ventricular and vascular properties,
resulting in unique routes along a natural history continuum.
Therefore, the evolution of PDD should be viewed in light of
the underlying disease contributing to DD.
Hypertension and peripheral vascular disease result in the
progression of DD via ventricular remodeling secondary to
increased afterload. Kane et al. (8) recently reported that
longitudinal evaluation of participants in the population-
based OCHFS (Olmsted County Heart Function Study)
cohort revealed that LV DD is highly prevalent, tends to
worsen over time, and is associated with advancing age. The
data suggests that persistence or progression of DD is a risk
factor for HF in elderly persons. Correa de Sa et al. (50)
reported that in a cohort of PDD patients, the 2-year
cumulative probability for development of HF according to
Framingham criteria was 1.9%; however, the 2-year cumu-
lative probability for development of any HF symptoms was
31.1%. It was also found that peripheral vascular disease and
hypertension were independently associated with the
progression of PDD to development of symptoms. The
authors, therefore, speculated that ventricular-arterial
interaction may be important for this progression.
Those with underlying renal disease are at higher risk of
developing HFpEF, given a chronically ﬂuid-elevated state.
In a cohort study by Vogel et al. (52), 388 subjects were
followed for a mean of 4 years to determine the progression
of PDD to symptomatic HF. Among those with PDD, at 1,
2, and 3 years of follow-up the cumulative probabilities for
development of symptomatic HF were 2.2%, 5.7%, and
11.6%, respectively. Through both univariable and multi-
variable analyses, they showed that age, right ventricular
systolic pressure, and renal dysfunction with glomerular
ﬁltration rate <60 ml/min were independently associated
with development of HF. Furthermore, patients with PDD
were more likely to develop atrial ﬁbrillation and cardiac
hospitalization for coronary artery disease, myocardial
infarction, or peripheral vascular disease. In addition, the
3-year mortality rate for PDD was found to be 10.1%.
Diabetic patients, especially those with poorly-controlled
blood sugars, may develop diabetic cardiomyopathy, patho-
logical changes leading to ﬁbrosis and remodeling of cardiac
muscle and leading to increased LV mass. In a recent study
by From et al. (53), a more speciﬁc PDD study group was
analyzed. In this study, all diabetes mellitus patients withtissue Doppler imaging of diastolic function in Olmsted
County, Minnesota, from 2001 to 2007 were identiﬁed and
followed to determine the probability of HF development
(53). Patients were excluded if they had a prior HF diag-
nosis. Overall, 1,760 patients were included, and 411 of
these had PDD. The 5-year cumulative probability of HF
development among the PDD patients with diabetes was
36.9% compared with 16.8% for those without PDD. The
1-year cumulative probability of HF development among the
PDD patients with diabetes was 13.1% compared with 5.2%
for those without PDD. Furthermore, the 5-year cumulative
probability of death among the PDD patients was 30.8%
compared with 12.1% for those without PDD.
It was also determined that PDD was associated with the
subsequent development of HF even after adjustment for
age, sex, body mass index, hypertension, coronary artery
disease, left atrial size, and LV muscle mass. In addition, for
every 1 U increase above 15 in the ratio of passive transmitral
LV inﬂow velocity to tissue Doppler imaging velocity of the
medial mitral annulus during passive ﬁlling (E/e
0
), there was
a 3% greater likelihood of HF development.
In his editorial comment regarding the study by From
et al. (53), Greenberg (54) emphasized the importance of
realizing that there is now evidence showing a linearly
increased risk for development of HF among diabetic
patients on the basis of E/e0. In addition, he noted that
diabetic patients with PDD who developed HF and/or died
did so at rates that were similar to those reported previously
for patients with asymptomatic LV SD (55). Although there
have been studies that suggest that poor glycemic control
among those with diabetes may increase progression to
HFpEF, it remains unclear whether treating hyperglycemia
will improve or reverse the condition (56). The pathology of
PDD, therefore, may not be directly related to hypergly-
cemia, but rather to oxidative stress and the structural
remodeling that occurs.
Coronary artery disease leads to ischemic cardiomyopathy,
and subsequent cardiac remodeling results in the develop-
ment of HF. Ren et al. (57) also provided information
regarding the natural history of PDD in a more speciﬁc
study group. They reviewed 693 subjects with coronary heart
disease (deﬁned as a history of myocardial infarction,
angiographic evidence of 50% stenosis in 1 coronary
vessel, previous evidence of exercise-induced ischemia using
treadmill electrocardiogram or stress nuclear perfusion
imaging, or history of coronary revascularization), normal
systolic function, and no history of HF. They found that 455
(66%) had normal LV diastolic function, 166 (24%) had
mild LV DD, and 72 (10%) had moderate to severe LV
DD. They also found that the presence of moderate
to severe LV DD was strongly predictive of incident
hospitalization for HF and death from heart disease.
Lam et al. (24) studied the risk of development of HF for
noncardiac risk factors, such as hemoglobin, creatinine, and
pulmonary function parameters. They reported that, with
adjustment for established HF risk factors and the presence
Table 2 Natural History of PDD and Subsequent Progression to Symptomatic HF
First Author (Ref. #) Year Population Incidence of Symptomatic HF Development
Correa de Sa et al. (50) 2010 PDD 2-yr incidence HF development: 1.9%
(2-yr incidence of any HF symptom: 31.1%)
Vogel et al. (52) 2012 PDD 1-yr incidence HF development: 2.2%
2-yr incidence HF development: 5.7%
3-yr incidence HF development: 11.6%
From et al. (53) 2010 PDD þ DM 1-yr incidence HF development: 13.1%
5-yr incidence HF development: 36.9%
Ren et al. (57) 2007 PDD þ CAD 3-yr incidence HF hospitalization: 8.4%
Lam et al. (24) 2011 PDD þ noncardiac 4-yr incidence HF development: 4%, 7%, 10%
(0, 1, 2 noncardiac risk factors, respectively)
Kane et al. (8) 2011 PDD (moderate to severe
diastolic dysfunction)
1-yr incidence HF development: 3%
3-yr incidence HF development: 7%
5-yr incidence HF development: 10%
Noncardiac includes renal, pulmonary, and hematologic factors.
CAD ¼ coronary artery disease; DM ¼ diabetes mellitus; HF ¼ heart failure; PDD ¼ pre-clinical diastolic dysfunction.
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412of cardiac SD and DD, subclinical renal impairment,
pulmonary airﬂow limitation, or anemia was associated with
30% increased risk of incident HF. These ﬁndings reinforce
the importance of HF as a systemic, and not purely cardiac,
disease. DD is a manifestation of systemic disease, as there is
a high association of noncardiac death with DD. Supporting
this concept, I-PRESERVE (Irbesartan in Heart Failure
With Preserved Ejection Fraction Study) (58) demonstrated
that diabetes, COPD, and renal dysfunction were inde-
pendent predictors of mortality and that, among those
HFpEF patients who died, there was a large proportion of
noncardiac deaths. The most common cause of death in
HFpEF patients was cardiac at 60%, with 26% from sudden
death, 14% from HF, 5% from myocardial infarction, and
9% from stroke. However, 30% died of noncardiac causes
that included renal, respiratory, and infectious causes.
Chen et al. (59) reported that uncontrolled hypertension,
new-onset atrial ﬁbrillation, infection, and myocardial
ischemia were frequently present in patients presenting with
incident HFpEF. This would suggest that both cardiac and
noncardiac systemic insults may have a role in inﬂuencing
the progression from PDD to HFpEF. Furthermore, McKie
et al. (60) reported that subjects with PDD have impaired
renal endocrine response to acute volume load.
In summary, the studies reviewed in this section do
provide useful natural history data regarding PDD (Table 2).
However, what remains unknown is the speciﬁc relationship
between PDD and the progression to HFpEF. Although
many patients progress from PDD to HFpEF, it is unclear
whether this relationship is linear, or how patients may
revert to a pre-clinical state after developing HFpEF. There
is a signiﬁcant proportion of patients with PDD who
subsequently develop HFpEF. However, not all people
with PDD progress, and those with the same degree of
DD can have vastly different clinical syndromes. This risk
of progression to HFpEF appears to be higher among
those with hypertension, peripheral vascular disease, renal
dysfunction, COPD, anemia, diabetes, or coronary heart
disease. It is important to note that, despite the importantcontributions of the data presented, disease progression in
speciﬁc comorbid conditions remains poorly established. On
the basis of the current data, we speculate that impairment in
cardiovascular, pulmonary, and renal reserve in response to
systemic insult may be a central key in differentiating
between patients with PDD that progress to develop
HFpEF and those that remain asymptomatic.
From a physiological level, this suggests that cardiovas-
cular, pulmonary, and renal reserve as well as extracardiac
oxygen delivery and utilization are important factors in
development of symptoms. From a clinical standpoint,
future investigations into frailty processes that predispose
one to greater stressor susceptibility may serve as one of the
keys to elucidating this relationship between PDD and
HFpEF. Clearly, understanding DD, including PDD, is
essential to decreasing patients’ morbidity and mortality.
Management of PDD
That which predisposes to the development of PDD is not
necessarily identical to that which propagates the disease to
symptomatic HF or HFpEF, although there may be signif-
icant overlap. In the epidemiology section, the development
of PDD was found to be associated with established
cardiovascular risk factors such as increasing age, coronary
artery disease, hyperlipidemia, metabolic syndrome, periph-
eral vascular disease, and diabetes (Fig. 1). Therefore, treat-
ment of these risk factors may prevent development of PDD.
However, once the diagnosis of PDD is established, the
natural history section demonstrated that in addition to the
cardiovascular comorbidities, noncardiac risk factors such as
renal impairment, pulmonary airﬂow limitation, or anemia
are involved in the progression of the disease to symptomatic
HFpEF (Fig. 1). Hence, the management of PDD can be
divided into 2 main categories: 1) prevention of development
of PDD; and 2) prevention of progression of PDD to
HFpEF.
Prevention of development of PDD. The current data
suggests that patients with PDD are diverse, with very
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disease, hyperlipidemia, metabolic syndrome, peripheral
vascular disease, and diabetes. Hence, the treatment or
prevention of PDD needs to be tailored to the underlying
cardiovascular comorbidities.
The work by Arnold et al. (61) from the HOPE (Heart
Outcomes Prevention Evaluation) study demonstrated that
an angiotensin-converting enzyme inhibitor for those at
high cardiovascular risk reduced the risk of development of
HF, especially among those with higher baseline blood
pressures, with a relative risk of 0.67. A substudy of
ALLHAT (Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial) assessed the relative
effect of chlorthalidone, lisinopril, and amlodipine in
preventing HF. It reported that diuretic agents are superior
to calcium-channel blockers in preventing HF in hyper-
tensive patients (62). Indeed, these studies suggested that
good hypertension control may lead to regression of PDD,
although this requires further validation (63). As discussed
in the natural history section, diabetes contributes to
progression of DD. Iribarren et al. (56) demonstrated that,
among those with diabetes, poor glycemic control may be
associated with the development of HF, suggesting the
importance of diabetes treatment for the prevention of DD
progression.
There are several trials that studied the modulation of LV
DD through pharmacological means. The Hong Kong dia-
stolic HF study demonstrated that, in an elderly group of
HF patients with normal EF, diuretic agents in combination
with an angiotensin-converting enzyme inhibitor or an
angiotensin receptor blocker improved LV diastolic function
longitudinally and led to decreased N-terminal pro–B-type
natriuretic peptide (NT-proBNP) levels (64). The SWEDIC
(Swedish Doppler echocardiographic study) showed that
carvedilol resulted in echocardiographic improvements in
patients with HFpEF (65). Studies are needed to determine
the efﬁcacy of these strategies in PDD to improve clinical
outcomes.
Prevention of progression of PDD to HFpEF. Given the
true paucity of PDD-speciﬁc treatment trials and the fact
that PDD can progress to HFpEF, the following discussion
will focus mainly on treatment of HFpEF. In a randomized,
double-blind, placebo-controlled trial by the Digitalis
Investigation Group (66), patients with HF and LV ejection
fraction >45% on digoxin had a risk ratio of 0.82 for the
combined outcome of death or hospitalization due to
worsening HF (95% conﬁdence interval: 0.63 to 1.07)
compared with placebo.
In the CHARM (Candesartan in Heart failure: Assess-
ment of Reduction in Mortality and morbidity)-Preserved
study, it was found that among patients with HF and
LVEF >40%, candesartan compared with placebo had
a moderate impact in preventing admissions for HF
(p ¼ 0.014), yet there was no difference in rates of cardio-
vascular death (67). In the I-PRESERVE study, patients
with HF and EF 45% had no signiﬁcant differences inoutcomes between irbesartan and placebo, including
a composite of all-cause mortality or hospitalization for
a cardiovascular cause (p ¼ 0.35), the overall rate of death
(p ¼ 0.98), and the rate of hospitalization for cardiovascular
causes (p ¼ 0.44) (68).
In the randomized, double-blind, placebo-controlled
PEP-CHF (Perindopril in Elderly People with Chronic
Heart Failure study, it was found that in the perindo-
pril group, there were improvements in functional class
(p < 0.030) and exercise capacity (p ¼ 0.011) as well as
fewer hospitalizations for HF (p ¼ 0.033) (69).
The 3 ongoing, randomized, double-blind, placebo-
controlled phase III trials regarding aldosterone antagonism
in HFpEF are the ARCTIC-D (Aldosterone-blockade
Randomized Controlled Trial in CHF–Diastolic), PIE-II
(Pharmacological Intervention in the Elderly II), and
TOPCAT (Trial of Aldosterone Antagonist Therapy in
Adults with Preserved Ejection Fraction Congestive Heart
Failure) trials. The ARCTIC-D study examines the effects
of spironolactone on collagen turnover and correlates that to
measures of LV mass regression and diastolic function on
magnetic resonance imaging after 4 months of aldosterone
blockade. The PIE-II study examines the effects of spi-
ronolactone on exercise tolerance and quality of life in elderly
patients with isolated HFpEF. The TOPCAT study eval-
uates the effectiveness of spironolactone therapy in reducing
all-cause mortality in patients who have HFpEF (70).
The Aldo-DHF (Aldosterone Receptor Blockade in
Diastolic Heart Failure) trial results were recently published,
and demonstrated that there was signiﬁcant improvement
of diastolic function on the basis of echocardiographic
measurements, but there were no signiﬁcant improvements
in exercise capacity, symptoms, or quality of life in patients
treated with spironolactone (71).
Finally, the RELAX (Phosphodiesterase-5 Inhibition to
Improve Clinical Status and Exercise Capacity in Diastolic
Heart Failure) study is a randomized, double-blind, placebo-
controlled trial examining the effects of sildenaﬁl on exercise
capacity and clinical status in patients with HFpEF (72).
This study did not demonstrate a signiﬁcant improvement in
exercise capacity or clinical status with sildenaﬁl adminis-
tration among those with HFpEF (43). However, even with
therapeutic PDE5 levels, there were minimal increases in
plasma cyclic guanosine monophosphate (cGMP). Further
studies may focus on the up-regulation of cGMP through
increased production by the nitric oxide pathway or
natriuretic peptide pathway.
Over the past several years, there have been investigations
into the use of ranolazine, an inhibitor of the late sodium
transmembrane current. This late sodium current diverts
extracellular sodium away from the sodium calcium
exchanger, therefore resulting in decreased intracellular
calcium removal. It is thought that delayed removal of
calcium leads to delayed relaxation and, therefore, diastolic
dysfunction. Recent evidence in rat models has also
proposed an additional mechanism of action for ranolazine,
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ization refractoriness and increase in conduction time (73).
Initial results are promising, and in mice models, ranolazine
has been shown to reverse diastolic dysfunction (74).
RALI-DHF (Ranolazine for the Treatment of Diastolic
Heart Failure), a small proof of concept randomized
double-blind trial, attempts to bridge the gap between basic
science research and clinical application (75). The recently
published results from the RALI-DHF trial demonstrated
that ranolazine infusion signiﬁcantly reduced LV end dia-
stolic pressure from 21.3 to 19.1 mm Hg and improved
hemodynamic measurements such as pulmonary capillary
wedge pressure, there was no improvement in the relaxation
parameter of rate of LV pressure decline, E/e0 ratio, or
NT-proBNP (76). Further large human trials should better
elucidate the efﬁcacy of ranolazine for HFpEF, and further
studies are necessary before consideration of ranolazine use
in the clinical setting.
As discussed in the pathophysiology section, nitric oxide
synthase uncoupling can occur with depletion of its cofactor
tetrahydrobiopterin and subsequently lead to DD given
impairment of cardiac relaxation. Recent promising work
has shown that supplementation of tetrahydrobiopterin may
prevent or reverse DD in hypertensive mice (47).
The use of antiﬁbrotic agents has also been studied in
rat models, and recent work has been promising. Tranilast,
a medication for asthma and other allergic disorders, has
antiﬁbrotic activity via inhibition of collagen synthesis in
ﬁbroblasts. It has previously been studied for prevention
of restenosis after coronary revascularization with mixed
results (77). Among diabetic rats, tranilast prevented
development of diastolic dysfunction (78). Given the
physiological action of this agent, it may also prevent pro-
gression of PDD.
Atrial dyssynchrony has been proposed as a potential
mechanism causing HFpEF. In a series of cases, Eicher
et al. (79) demonstrated that interatrial mechanical delay was
present among 59% of subjects with HFpEF, but none in
control subjects. This led to the proposal of atrial resynch-
ronization therapy for treatment of HFpEF as well as
prevention of atrial ﬁbrillation development (80). Further-
more, Kim et al. (81) demonstrated that LV dyssynchrony
may also play an important role in DD, both among those
with HF symptoms (HFpEF) and without (PDD).
The use of B-type natriuretic peptide (BNP) in PDD has
also been studied. Recent evidence has shown that im-
pairment in renal endocrine and natriuretic response may
contribute to the underlying physiology of PDD. Following
volume expansion, subjects with PDD were less able to
adapt given decreased urinary excretion of cGMP and
sodium. In the setting of LV DD, a state of low levels of
cGMP and high oxidative stress exists. Given this patho-
physiological mechanism, McKie et al. (60) showed that
administration of subcutaneous BNP may restore the normal
physiological cGMP and sodium excretion post-volume
expansion.Neprilysin is an enzyme that degrades biologically active
natriuretic peptides including BNP. NT-proBNP, which
can serve as a marker of HF severity, is not affected by
neprilysin. Therefore, neprilysin inhibitors enhance the
concentration and effects of endogenous BNP and may lead
to improved cardiac function. In a recent multicenter,
randomized, double-blind trial of 266 subjects with HFpEF,
those given an angiotensin receptor neprilysin inhibitor had
signiﬁcantly lower NT-proBNP levels after 12 weeks
compared with those who received valsartan (82).
Gaps in Knowledge/Areas for Future Research
As noted previously, there are very few original studies that
have focused on PDD. As a result, PDD as an entity
remains poorly understood. Although the baseline charac-
teristics of clinical DD have been established, the only
natural history studies to date (Correa de Sa et al. [50],
Vogel et al. [52], and Kane et al. [8]) that are focused
broadly on PDD were limited by a small, enriched
population (4,8,9,50,53). These and the work by From et al.
(53), Ren et al. (57), and Lam et al. (24) are the only studies
at present that have focused closely on the progression of
PDD to HF and the associated risk factors for this
progression.
It remains unknown what the speciﬁc relationship is
between PDD and the progression to HFpEF. Hence,
future prospective natural history and physiological studies
are needed to better deﬁne the mechanisms of progression of
PDD to HFpEF.
The current data suggests that patients with PDD are
diverse, with very different cardiovascular comorbidities such
as coronary artery disease, hyperlipidemia, metabolic
syndrome, peripheral vascular disease, and diabetes. Hence,
the treatment for PDD needs to be tailored to the underlying
cardiovascular comorbidities.
In addition to the cardiovascular comorbidities, noncardiac
risk factors such as renal impairment, pulmonary airﬂow
limitation, and anemia are suggested to be involved in the
progression of PDD to symptomatic HFpEF. Hence, we
hypothesize that whereas therapeutic strategies focusing on
cardiovascular comorbidities have not been shown to be
effective in improving outcomes in HFpEF, therapeutic
strategies aimed at both systemic and cardiovascular
comorbidities may play a crucial role in delaying the
progression from PDD to HFpEF as well as improve
outcomes in patients with HFpEF. This hypothesis needs to
be tested in clinical trials comparing patients with PDD and
those with HFpEF.
Conclusions
Although PDD remains poorly understood, it has clear
clinical signiﬁcance. PDD is prevalent and has been shown
to progress to overt HF (HFpEF). In the setting of
a worsening HF epidemic, further PDD research will be
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415essential to better characterize this entity, to identify risk
factors for progression to overt HF, and to identify thera-
peutic interventions to delay the progression to HFpEF.
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